Programmed death 1 (PD-1) is a cell surface co-receptor in the CD28/CTLA-4 T-cell family and functions as a down regulator of the immune system through a dual mechanism of inhibition.PD-1 is expressed on activated T-cells, B-cells, and myeloid cells, and is a marker of angioimmunoblastic lymphoma and suggests a unique cell of origin for this neoplasm.The presence of PD-1 positive tumor-infiltrating lymphocytes (TIL) has been associated with poor prognosis in human breast cancers and may be useful in antibody therapy targeting the PD-1/PD-L1 signaling pathway. Treatments targeting PD-1 and its ligand, PD-L1, have also shown encouraging results in non-small-cell lung cancer, renal cell carcinoma and melanoma.
Recombinant full length protein corresponding to Human PD-1. The immunogen contains the specific extracellular domain of huPD1 (L25-Q167).
1.Iwai Y., Okazaki T., Nishimura H., Kawasaki A., Yagita H., Honjo T. Immunol. Lett. 83:215-220(2002).
2.James E.S., Harney S., Wordsworth B.P., Cookson W.O., Davis S.J., Moffatt M.F. Genes Immun. 6:430-437(2005).